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Small-moleculeTankyrases 1 and 2, the specialized members of the ARTD protein family, are druggable biotargets whose
inhibition may have therapeutic potential against cancer, metabolic disease, fibrotic disease, fibrotic
wound healing and HSV viral infections. We have previously identified a novel tankyrase inhibitor scaf-
fold, JW55, and showed that it reduces mouse colon adenoma formation in vivo. Here we expanded the
scaffold and profiled the selectivity of the compounds against a panel of human ARTDs. The scaffold also
enables a fine modulation of selectivity towards either tankyrase 1 or tankyrase 2. In order to get insight
about the binding mode of the inhibitors, we solved crystal structures of the compounds in complex with
tankyrase 2. The compounds bind to the adenosine pocket of the catalytic domain and cause changes in
the protein structure that are modulated by the chemical modifications of the compounds. The structural
analysis allows further rational development of this compound class as a potent and selective tankyrase
inhibitor.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Tankyrase 1 (TNKS1/PARP-5a/ARTD5) and tankyrase 2 (TNKS2/
PARP-5b/ARTD6) are protein modifying enzymes, which have
recently been in the focus of intense search for specific inhibitors.
Tankyrases are composed of multiple protein domains and share a
catalytic ARTD domain responsible for poly(ADP-ribosyl)ation of
target proteins, a SAM domain involved in tankyrase oligomeriza-
tion, and ankyrin repeats which mediate interactions with other
proteins. Tankyrases regulate the stability of target proteins by
binding to a specific motif and attaching poly(ADP-ribose) chains
to the target protein. The poly(ADP-ribose) chain serves as a recog-
nition site for the E3 ubiquitin ligase RNF146 that induces ubiqui-
tination leading to proteasomal degradation.1,2
The most extensively studied pathways in which tankyrases
have been shown to elicit a regulatory function are centriole elon-
gation and mitotic spindle formation, telomere cohesion, exocyto-
sis of IRAP and GLUT4 containing trans-Golgi vesicles and the
WNT/b-catenin signaling pathway.3–16
Here we studied a recently identified tankyrase inhibitor JW55
(1)15 and its analogs. We used a cell-based SuperTOP-Luciferase/
Renilla (ST-Luc/Ren) reporter assay to screen compounds for theirinhibition of canonical WNT/b-catenin signaling. With a biochem-
ical assay we confirmed that the analogs specifically inhibit tan-
kyrases and profiled the selectivity of the compounds against
eight other human ARTDs. To provide structural insights on their
inhibitory mechanism, we determined crystal structures of the
most potent analogs and the parent compound 1 in complex with
TNKS2 and show that the inhibitors anchor to the adenosine sub-
site of the donor NAD+ binding groove. The structures explain the
high selectivity of the scaffold and provide further routes for
enhancing compound potency.
The primary hit 1moderately inhibited tankyrases and WNT/b-
catenin signaling.15 A selection of JW55 (1) analogs (Table 1) were
tested for their ability to inhibit b-catenin-mediated canonical
WNT signaling at various compound concentrations. This ST-Luc/
Ren assay was performed using a WNT3a-induced and stably
transfected HEK293 cell line (ST-Luc/Ren HEK293), as reported ear-
lier.14,17 In vitro inhibition, as measured by biochemical assay com-
plemented the ST-Luc/Ren assay, showed moderate potency of 1
towards tankyrases (TNKS1 IC50 1.80 lM, TNKS2 IC50 2.01 lM,
ST-Luc/Ren IC50 1.23 lM), which is in agreement with a previously
measured value by an independent biochemical activity assay.15
Compounds based on the core structure 1 with substitutions at
the furan ring exhibited modest improvements on inhibiting
canonical WNT/b-catenin signaling as compared to 1 (Table 1).
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2 and improved the cellular IC50 to 0.79 lM. Interestingly, 2 is a
selective inhibitor of TNKS2 with IC50 0.26 lM but has poor
potency towards TNKS1 (IC50 11 lM). Despite this isoform selectiv-
ity 2 stabilized AXIN1 and destabilized non-phoshorylated b-cate-
nin moderately better than 1 in both HEK293 cells and SW480 cellsTable 1
JW55 analogs as tankyrase inhibitors
Compound
TNKS1
1 1.80 lM (5
2 11.08 lM
3 0.69 lM (6
4 0.57 lM (6
5 1.13 lM (5
6 0.55 lM (6
7 0.046 lM
Biochemical IC50 and corresponding pIC50 ± SEM (n = 3) and ST-Luc/Ren IC50 ± SDM are r
biochemical and ST-Luc/Ren data.17(Fig. 1). Substituting the furan group with 2-methylfuran led to 3
and gave an improved cellular IC50 of 0.38 lM (TNKS1 IC50
0.69 lM; TNKS2 IC50 2.30 lM). Altering the central p-phenylene
ring of 1 to a 2-chloro-p-phenylene led to 4 and showed a cellular
IC50 of 0.38 lM (TNKS1 IC50 0.57 lM; TNKS2 IC50 2.15 lM). Substi-
tuting the furan group in 4 with a 2-methyl oxazole gave 5 but didIC50 (pIC50 ± SEM) ST-Luc/Ren
IC50 ± SDM (lM)
PDB code
TNKS2
.74 ± 0.10) 2.01 lM (5.70 ± 0.12) 1.23 ± 0.60 5ADQ
(4.96 ± 0.05) 0.26 lM (6.59 ± 0.19) 0.79 ± 0.05 ND
.16 ± 0.02) 2.30 lM (5.64 ± 0.21) 0.38 ± 0.20 5ADR
.25 ± 0.03) 2.15 lM (5.67 ± 0.07) 0.36 ± 0.10 5ADS
.95 ± 0.18) 2.23 lM (5.65 ± 0.09) 0.69 ± 0.04 5ADT
.26 ± 0.09) 0.037 lM (7.43 ± 0.08) 1.91 ± 0.10 5AEH
± 0.001 0.025 lM ± 0.006 0.05 ± 0.02 4HYF
eported. Data for 7 is from Voronkov and co-workers and ± SDM is shown for both
Figure 1. Western blot analysis shows that both 1 and 2 dose-dependently (24 h incubation) mediate decreased TNKS1/2 abundance, increased AXIN1 stability and in
addition degradation of active (non-N terminal phosphorylated) and total b-catenin in (A) WNT3a-stimulated (+) HEK293 cells and (B) APC-mutated SW480 CRC cells.
Compound treatment concentrations (lM) are indicated while the corresponding controls are in 0.1% DMSO (). ACTIN antibody documents equal protein loading. The blots
show representative data derived from multiple experiments.
Table 2
Profiling 4 and 6 against a panel of human ARTDs
Compound IC50 (lM)
ARTD1 ARTD2 ARTD3 ARTD4 ARTD7 ARTD8 ARTD10 ARTD12
4 >100 >100 >100 >100 >10a >10a >10a >10a
6 77 >100 >100 >100 >10a >10a >10a >10a
a Limited by assay DMSO tolerance.
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(TNKS1 IC50 1.13 lM; TNKS2 IC50 2.23 lM).
The weak biochemical potency of 2 towards TNKS1 prompted us
to measure the alterations in the protein amounts of tankyrase, the
tankyrase target and structural protein of the b-catenin degrada-
some AXIN1, along with the mediator of canonical WNT signaling
b-catenin using Western blot analysis. Wild type HEK293 cells
and SW480 cells were incubated with 1 and 2 at various concentra-
tions for 24 h. The analysis confirmed that the observed ST-Luc/Ren
inhibition in HEK293 cells can be rationalized by tankyrase inhibi-
tion also with 2 as it results in (i) altered levels of TNKS1/2, (ii)
increased AXIN1 abundance and (iii) decreased quantities of non-
phosphorylated and transcriptional active b-catenin (Fig. 1). Inter-
estingly, treatment with 1 and 2 decreased protein levels of both
TNKS1 and TNKS2 upon treatment in the two cell lines. This obser-
vation is opposite to the observed stabilization of these two pro-
teins after treatment with the tankyrase inhibitor XAV939.4
A more radical change of the structure of the molecule, retain-
ing the core structure from 2, which showed the highest selectivity
to TNKS2 in an enzymatic assay and combining N-(2-chlorophenyl)
and pyrimidine groups based on SAR studies of 7 (G007-LK)17,18
yielded the most potent compound (TNKS1 IC50 0.55 lM; TNKS2
IC50 0.037 lM) that still retained a moderate preference to inhibit-
ing TNKS2. However, the cellular IC50 (1.91 lM) was reduced when
compared with the control compound 7 (Table 1).The selectivity of 4 and 6 were tested with eight other ARTDs,
namely ARTD1, 2, 3, 4, 7, 8, 10, and 12 (Table 2). The compounds
displayed high selectivity for tankyrases and had negligible inhibi-
tion over the other ARTD enzymes tested.
The binding modes of 1 and analogs 3, 4, 5, and 6were analyzed
by soaking them to crystals of the TNKS2 ARTD domain. The cat-
alytic domains of TNKS1 and 2 have 94% sequence identity with
all the residues conserved in the donor NAD+ binding site.19
Despite multiple attempts, we were unable to soak 2 to crystals.
The compounds bind to the adenosine subsite of the donor NAD+
binding groove and induce an opening of the D-loop lining the site
(Fig. 2).
Binding of the compounds 1, 3, 4, and 5 is largely mediated by
hydrophobic interactions. The tetrahydropyran rings of the com-
pounds extend towards the nicotinamide site and are lined by
hydrophobic Ile1051, Gly1053, Tyr1060, Tyr1071, and Ile1075
(Fig. 2a–d). The 4-methoxyphenyl moiety of the compounds is sit-
uated in a hydrophobic pocket between F- and G-loops lined by
Ser1033, Pro1034, Phe1035, Ile1051, and Ile1075. The aromatic
furan ring is bound between an a-helix containing hydrophobic
Ala1038 and Ile1039 and to His1048 from the D-loop. The com-
pounds are almost parallel with His1048 forming a stacking inter-
action with it.
1, 3, 4, and 5 form two hydrogen bonds to the main chain
amides of Tyr1060 and Asp1045 via their carbonyl oxygens. Similar
Figure 2. Co-crystal structures of the inhibitors with the catalytic domain of TNKS2: (A) 1, (B) 3, (C) 4, (D) 5, (E) 6 conformation 1, and (F) 6 conformation 2. Hydrogen bonds
are displayed as black dotted lines. Halogen bonds in (F) are depicted as blue dotted lines.
T. Haikarainen et al. / Bioorg. Med. Chem. Lett. 26 (2016) 328–333 331interactions are also present in the other inhibitors binding to this
site, namely WIKI4, IWR-1, and G007-LK.17,20,21
Despite similar structures there are some differences in the
binding modes of 3, 4, and 5 when compared to 1. The methyl
substitution in the furan ring of 3 does not induce large changes
in the binding mode when compared to 1 (Fig. 2a and b). How-
ever, it allows for more efficient hydrophobic interactions with
the binding site namely with Phe1035, Ala1038 and Lys1042. In
4, the substitution of the chlorine in the central phenyl group
causes a shift in the position of the D-loop in (Fig. 2c). Ile1051
moves 1.1 Å closer to the compound, and Tyr1050 is pushed
0.9 Å away from the binding site. Interestingly, 4 induces a 75
turn of Phe1035 at the opposing F-loop allowing a water mole-
cule to bind between the inhibitor and the residue. Compound
5 shares the methyl and chlorine substitutions of 3 and 4, respec-
tively. However, it has lowered potency compared to the two
compounds, most likely due to the amide substitution in thefuran ring, which disturbs the hydrophobic interactions made
by the ring with Lys1042 (Fig. 2d).
Compound 6 binds to the same pocket in the TNKS2 catalytic
domain (Fig. 2e and f). Similarly to the JW55 analogs the com-
pound forms mainly hydrophobic interactions with the protein,
but also the two hydrogen bonds to Asp1045 and Tyr1060 are pre-
sent. Notably, the 6 is bound in two conformations in the crystal
structure with equal occupancy. The difference between two con-
formers is a rotation of pyrimidinyl and chlorophenyl groups
around the amide bond in a way that the aromatic rings switch
places in the binding pocket. In the first conformation (Fig. 2e)
chlorophenyl adopts a similar conformation as seen previously
for 7 (Supplementary Fig. 1).17 In the second conformation (Fig. 2f),
the compound forms a halogen bond with Gly1032 and a water
molecule located near the nicotinamide binding site, and an addi-
tional hydrogen bond is formed between the oxygen of methoxy-
phenyl group and a water molecule. Additional substitutions in
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Pyrimidinyl (conformation 1) and chlorophenyl (conformation 2)
groups are p-stacking against Tyr1060. In contrast to other com-
pounds the shorter linker between pyrimidinyl/chlorophenyl and
central benzene ring causes an almost 90 rotation of latter due
to steric clashes. Binding of 6 causes changes in the D-loop.
Ile1051 is moved out from the binding site and is not involved in
interactions. Tyr1050 instead, moves towards the compound form-
ing additional hydrophobic interactions. Interestingly, the larger
methoxyphenyl substitution does not induce major changes com-
pared to the furan and oxazole analogs. Only Lys1042 is moved
away from the compound although this residue is not well ordered
in the crystal structure.
Compounds based on the JW55 scaffold share similar interac-
tions as other recently published inhibitors binding to the adeno-
sine subsite of tankyrases.17,21 Inhibitors are selective towards
tankyrases over eight other ARTD isoenzymes tested and thus the
scaffold adds further chemical space to develop specific tankyrase
inhibitors. Structural studies of the JW55 scaffold implicated sev-
eral possible routes to further improve the potency of these inhibi-
tors. Other inhibitors binding to this site contain bigger
substitution in the place of the furan ring which forms parallel
stacking interaction with His1048. The substitution of the small
aromatic furan with larger ring systems would be a logical starting
point to further improve compound potency. JW55 andWIKI4 both
contain a methoxyphenyl moiety extending towards the G-loop.
However, because of slightly different orientation of the group,
the oxygen of the methoxy group can interact with the backbone
amide of Ile1075 in case of WIKI4.21 Other hydrophilic substitu-
tions at the place of the methoxy group could be tested in order
to form an interaction with Ile1075. The tetrahydropyran ring
extending towards the nicotinamide binding site is close to several
potential hydrogen bond donors and acceptors that may be
addressed. These include the carbonyl oxygen of Ile1051 and
amides of Met1054 and Gly1053 as well as hydroxyl of Tyr1071.
The compounds generally had similar potencies towards both
tankyrase isoforms. However, 2 displayed a 40-fold selectivity
towards TNKS2 in the enzymatic activity assay. Although we were
not able to get a crystal structure of the TNKS2-2 complex, there
are no structural differences between TNKS1 and 2, which could
explain the TNKS2 selectivity of the compound. Also 6 displayed
15-fold selectivity towards TNKS2. Both compounds 2 and 6 share
an m-methoxyphenyl group. Isoform selectivity at this range has
been previously observed for tankyrase inhibitors, although a com-
prehensive rationale for tankyrase isoform selectivity is currently
lacking.22–26 Most likely differences in the dynamics of the donor
NAD+binding sites between the isoforms lead to the observeddiffer-
ences in the potencies. However, despite the differential biochemi-
cal selectivity of 2 to TNKS2, the effect of 2 on protein stability was
similar in the cellular assay and in the same dose range as the effect
of compound 1 (1 showed no significant selectivity to either tan-
kyrases). These data indicate functional redundancy of both tankyr-
ase in the context of AXIN stabilization and b-catenin turnover.
Despite the moderate potency of the chemotype, its high target
selectivity along with promising in vitro as well as in vivo tumor
inhibition data15 demonstrates that the compound scaffold has
potential to be developed further towards a functional tankyrase
and WNT inhibitor for research and clinical purposes. We have
studied the detailed binding modes of the inhibitor series using
protein crystallography and could therefore provide initial struc-
ture activity relationship for structure-based design. Inhibitors
binding to the adenosine subsite display a high selectivity towards
tankyrases making this class of inhibitors attractive to further
development. Merging of the features from 1 and 7 was successful
and yielded a compound 6 which is a potent and selective tankyr-
ase inhibitor. Structure–activity relationship data of both com-pounds can now be combined in order to improve the cellular
potency of this chimeric scaffold.
Accession codes: Coordinates and structure factors have been
deposited to the protein data bank with codes 5ADQ, 5ADR,
5ADS, 5ADT, and 5AEH for TNKS2-1, TNKS2-3, TNKS2-4, TNKS2-5,
and TNKS2-6, respectively.Acknowledgments
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